|
1
|
Coleman RL, Monk BJ, Sood AK and Herzog
TJ: Latest research and treatment of advanced-stage epithelial
ovarian cancer. Nat Rev Clin Oncol. 10:211–224. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vaughan S, Coward JI, Bast RC Jr, Berchuck
A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R,
Etemadmoghadam D, et al: Rethinking ovarian cancer: Recommendations
for improving outcomes. Nat Rev Cancer. 11:719–725. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pliarchopoulou K and Pectasides D:
Epithelial ovarian cancer: Focus on targeted therapy. Crit Rev
Oncol Hematol. 79:17–23. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cannistra SA: Cancer of the ovary. N Engl
J Med. 351:2519–2529. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Holohan C, Van Schaeybroeck S, Longley DB
and Johnston PG: Cancer drug resistance: An evolving paradigm. Nat
Rev Cancer. 13:714–726. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yin F, Liu L, Liu X, Li G, Zheng L, Li D,
Wang Q, Zhang W and Li L: Downregulation of tumor suppressor gene
ribonuclease T2 and gametogenetin binding protein 2 is associated
with drug resistance in ovarian cancer. Oncol Rep. 32:362–372.
2014.PubMed/NCBI
|
|
8
|
Gyorffy B, Lánczky A and Szállási Z:
Implementing an online tool for genome-wide validation of
survival-associated biomarkers in ovarian-cancer using microarray
data from 1287 patients. Endocr Relat Cancer. 19:197–208. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cerami E, Gao J, Dogrusoz U, Gross BE,
Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et
al: The cBio cancer genomics portal: An open platform for exploring
multidimensional cancer genomics data. Cancer Discov. 2:401–404.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gao J, Aksoy BA, Dogrusoz U, Dresdner G,
Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al:
Integrative analysis of complex cancer genomics and clinical
profiles using the cBioPortal. Sci Signal. 6:pl12013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Edgar R, Domrachev M and Lash AE: Gene
Expression Omnibus: NCBI gene expression and hybridization array
data repository. Nucleic Acids Res. 30:207–210. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu X, Zou J, Su J, Lu Y, Zhang J, Li L
and Yin F: Downregulation of transient receptor potential cation
channel, subfamily C, member 1 contributes to drug resistance and
high histological grade in ovarian cancer. Int J Oncol. 48:243–252.
2016.PubMed/NCBI
|
|
13
|
Mostafavi S, Ray D, Warde-Farley D,
Grouios C and Morris Q: GeneMANIA: A real-time multiple association
network integration algorithm for predicting gene function. Genome
Biol. 9:(Suppl 1). S42008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Warde-Farley D, Donaldson SL, Comes O,
Zuberi K, Badrawi R, Chao P, Franz M, Grouios C, Kazi F, Lopes CT,
et al: The GeneMANIA prediction server: Biological network
integration for gene prioritization and predicting gene function.
Nucleic Acids Res. 38:(Web Server). W214–W220. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jenssen TK, Laegreid A, Komorowski J and
Hovig E: A literature network of human genes for high-throughput
analysis of gene expression. Nat Genet. 28:21–28. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hedditch EL, Gao B, Russell AJ, Lu Y,
Emmanuel C, Beesley J, Johnatty SE, Chen X, Harnett P, George J, et
al: Australian Ovarian Cancer Study Group: ABCA transporter gene
expression and poor outcome in epithelial ovarian cancer. J Natl
Cancer Inst. 106:1062014. View Article : Google Scholar
|
|
17
|
Liu X, Gao Y, Zhao B, Li X, Lu Y, Zhang J,
Li D, Li L and Yin F: Discovery of microarray-identified genes
associated with ovarian cancer progression. Int J Oncol.
46:2467–2478. 2015.PubMed/NCBI
|
|
18
|
Li M, Balch C, Montgomery JS, Jeong M,
Chung JH, Yan P, Huang TH, Kim S and Nephew KP: Integrated analysis
of DNA methylation and gene expression reveals specific signaling
pathways associated with platinum resistance in ovarian cancer. BMC
Med Genomics. 2:342009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yin F, Liu X, Li D, Wang Q, Zhang W and Li
L: Tumor suppressor genes associated with drug resistance in
ovarian cancer (Review). Oncol Rep. 30:3–10. 2013.PubMed/NCBI
|
|
20
|
Liu X, Gao Y, Lu Y, Zhang J, Li L and Yin
F: Oncogenes associated with drug resistance in ovarian cancer. J
Cancer Res Clin Oncol. 141:381–395. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu X, Gao Y, Lu Y, Zhang J, Li L and Yin
F: Upregulation of NEK2 is associated with drug resistance in
ovarian cancer. Oncol Rep. 31:745–754. 2014.PubMed/NCBI
|
|
22
|
Liu X, Gao Y, Lu Y, Zhang J, Li L and Yin
F: Downregulation of NEK11 is associated with drug resistance in
ovarian cancer. Int J Oncol. 45:1266–1274. 2014.PubMed/NCBI
|
|
23
|
Yin F, Liu X, Li D, Wang Q, Zhang W and Li
L: Bioinformatic analysis of chemokine (C-C motif) ligand 21 and
SPARC-like protein 1 revealing their associations with drug
resistance in ovarian cancer. Int J Oncol. 42:1305–1316.
2013.PubMed/NCBI
|
|
24
|
Wong KF, Xu Z, Chen J, Lee NP and Luk JM:
Circulating markers for prognosis of hepatocellular carcinoma.
Expert Opin Med Diagn. 7:319–329. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kim HS, Koh JS, Choi YB, Ro J, Kim HK, Kim
MK, Nam BH, Kim KT, Chandra V, Seol HS, et al: Chromatin CKAP2, a
new proliferation marker, as independent prognostic indicator in
breast cancer. PLoS One. 9:e981602014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kim YW, Eom BW, Kook MC, Kim HS, Kim MK,
Hwang HL, Chandra V, Poojan S, Song Y, Koh JS, et al: Clinical
implications of proliferation activity in T1 or T2 male gastric
cancer patients. Exp Mol Med. 47:e1932015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang Z, Wang A, Sun B, Zhan Z, Chen K and
Wang C: Expression of CLDN1 and CLDN10 in lung adenocarcinoma in
situ and invasive lepidic predominant adenocarcinoma. J
Cardiothorac Surg. 8:952013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Koie T, Ohyama C, Hatakeyama S, Imai A,
Yoneyama T, Hashimoto Y, Yoneyama T, Tobisawa Y, Hosogoe S,
Yamamoto H, et al: Significance of preoperative
butyrylcholinesterase as an independent predictor of biochemical
recurrence-free survival in patients with prostate cancer treated
with radical prostatectomy. Int J Clin Oncol. 21:379–383. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Koie T, Ohyama C, Yamamoto H, Hatakeyama
S, Imai A, Yoneyama T, Hashimoto Y, Kitayam M and Hirota K:
Significance of preoperative butyrylcholinesterase as an
independent predictor of survival in patients with muscle-invasive
bladder cancer treated with radical cystectomy. Urol Oncol.
32:820–825. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Willis S, Villalobos VM, Gevaert O,
Abramovitz M, Williams C, Sikic BI and Leyland-Jones B: Single gene
prognostic biomarkers in ovarian cancer: A meta-analysis. PLoS One.
11:e01491832016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nagele F, Petru E, Medl M, Kainz C, Graf
AH and Sevelda P: Preoperative CA 125: An independent prognostic
factor in patients with stage I epithelial ovarian cancer. Obstet
Gynecol. 86:259–264. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tang A, Kondalsamy-Chennakesavan S, Ngan
H, Zusterzeel P, Quinn M, Carter J, Leung Y and Obermair A:
Prognostic value of elevated preoperative serum CA125 in ovarian
tumors of low malignant potential: A multinational collaborative
study (ANZGOG0801). Gynecol Oncol. 126:36–40. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Poersch A, Grassi ML, Carvalho VP,
Lanfredi GP, Palma CS, Greene LJ, de Sousa CB, Carrara HH, Dos
Candido Reis FJ and Faça VM: A proteomic signature of ovarian
cancer tumor fluid identified by highthroughput and verified by
targeted proteomics. J Proteomics. 145:226–236. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Seo HW, Rengaraj D, Choi JW, Ahn SE, Song
YS, Song G and Han JY: Claudin 10 is a glandular epithelial marker
in the chicken model as human epithelial ovarian cancer. Int J
Gynecol Cancer. 20:1465–1473. 2010.PubMed/NCBI
|
